Objective: Endografts (eg, aortic aneurysm device or covered stent) are increasingly being used to temporize or treat arterial and graft infections in inaccessible areas, in patients with compromised anatomy, or in the presence of active bleeding or rupture. This summary examines the evidence for "in situ" endografting in the treatment these conditions.
Primary and secondary arterial infections and graft infections are associated with a high mortality and morbidity and pose a significant clinical problem. Endovascular techniques, including covered stents (ie, endografts), do offer an avenue to control hemorrhage and reduce immediate mortality and morbidity related to the primary condition. As a result, they are increasingly being used to temporize or treat arterial and graft infections in inaccessible areas, in patients with compromised anatomy or presenting with active bleeding or rupture, and in patients with a very high physiologic risk. Most of the publications in the field are retrospective case and cohort reports. There are no societal guidelines to guide the application of endovascular therapies in these conditions, and their use falls outside the instructions for use and the indications approved by the United States Food and Drug Administration and other regulatory authorities. This summary examines the evidence for "in situ" endografting in the treatment of arterial and graft infections in various vascular beds.
METHODS
A two-level search strategy of the literature (MEDLINE, PubMed, Google Scholar, and The Cochrane Library) was performed for relevant articles listed between January 2000 and December 2015. The searches were limited to studies in the English language based in humans and to the first 20 chronologically listed pages (w200 hits) in the case of Google Scholar. Search terms comprised guidelines, recommendations, metaanalysis, review, endovascular, arterial infection, arteritis, infected graft, mycotic aneurysm, and stent graft. After we identified relevant studies, we manually searched secondary sources, such as references, reviews, and commentaries, to identify additional materials. The review was confined to patients with primary and secondary bacterial or viral arterial infections, with or without fistulization, and infection of bypass grafts and arteriovenous accesses. For the purposes of this summary, endografts can be considered to be an aortic aneurysm device or a covered stent.
Endografts in aortic infection
Aortic infections. Aortic infections can run the spectrum of aortitis, perigraft infection, and aortoenteric or aortobronchial fistulae. Mycotic aortic aneurysms remain a rare cause (<2%) of aortic aneurysms; high mortality rates (13%-40%) have been associated with open repair of these entities (Figs 1 and 2 ). Kan et al 1 performed a systematic review in 2007 of 48 patients abstracted from 22 reports. The 30-day survival rate for these patients was w90%, and the 2-year survival rate was w82%. A univariate analysis model showed patient age $65 years, presence of a rupture of the aneurysm, and documented fever at the time of operation were significant predictors of persistent infection after the endovascular intervention. Use of preoperative antibiotics for >1 week and an adjunct procedure combined with endovascular aneurysm repair (EVAR) were factors that were considered protective against persistent infection. When a multivariate analysis was applied, rupture of aneurysm and fever were the only the only significant independent predictors identified. Further work by Kan et al 2 in 2010 identified additional factors of Salmonella spp infection and leukocytosis as contributing to aneurysm-related mortality and morbidity. Staphylococcus aureus is increasingly identified as a pathogen in these cases. 3 Placement of an endograft alone was not a significant factor in aneurysm-related mortality and morbidity, 2 but a persistent infection after EVAR was closely associated with a poor prognosis. A recent international collaboration at 16 European centers to elucidate the durability of stent grafts in the treatment of mycotic aortic aneurysms reported good shortterm outcome of 91% survival at 30 days, but fatal infection-related complications were high in the first postoperative year (19%). 4 Infection-related death occurred in 23 patients (19%), and 40% of the deaths occurred after discontinuation of antibiotic treatment. A Cox regression analysis model identified non-Salmonella-positive culture as a predictor for late infection-related death. 4 There remains no indication for an endograft in the setting of a perigraft infection unless there is evidence of a complication such as pseudoaneurysm, fistula formation, or hemorrhage. Aortoenteric fistula. An aortoenteric fistula has been defined as an abnormal communication between the aortic lumen and a bowel lumen. The incidence of aortoenteric fistula has been reported between 0.02% and 0.07% in autopsy studies and <1% in patients after abdominal aortic surgery. 5 Endovascular repair of the thoracic or abdominal aorta will control immediate hemorrhage but does not address the fistulous connection between the organ and the blood vessel. As a result, the stent graft can be considered to be a continuing source of infection. Multiple reports have indicated short-term success of endograft placement to control hemorrhage from the thoracic or abdominal aorta. In a recent meta-analysis of EVAR for this condition by Kakkos et al, 6 the 30-day mortality was reported at 8.5%. Recurrent bleeding developed in 19% of patients during follow-up and occurred more frequently in aortoenteric fistulae caused by cancer. The authors reported a rate of freedom from recurrent bleeding of 71.5% at 24 months. Freedom from sepsis was 64% at 24 months, and the freedom from combined rebleeding and sepsis was 59% at 24 months. Importantly, patients who did not undergo repair of any intestinal defects had a higher rate of combined recurrence and sepsis compared with patients who did (100% vs 52%). 6 Total aortoenteric fistularelated mortality was 15% at 12 months and 19% at 24 months. Recurrence of the aortoenteric fistula was associated with increased mortality (P ¼ .001). 6 Evidence of sepsis preoperatively was also associated with an unfavorable outcome by Antoniou et al 7 in a similar set of patients. Antoniou et al 7 reported that persistent, recurrent, or new infection or the occurrence of recurrent hemorrhage, or both, was documented in 44% of the patients during a mean follow-up period of 13 months. There was threefold increased risk of persistent/recurrent infection in secondary, compared with primary, aortoenteric fistulae. 7 Overall patient survival rates were 68% at 12 months and 52% at 24 months. Factors that determined a poor prognosis were perioperative sepsis, fistula from the large bowel, placement of a tube graft, absence of an intestinal repair, and recurrence of an aortoenteric fistula. 6 The presence of a persistent infection, recurrence of the infection, or development a new infection after intervention was associated with worse 30-day and overall survival compared with those who did not have manifestations of continued sepsis. 7 Aortoesophageal fistula. The reported incidence of aortoesophageal fistula is 0.01% to 0.07% of the general population. Patients with an aortoesophageal fistula present commonly in with hypovolemic shock (33% vs 13%; P ¼ .012) and manifest signs of systemic infection (36% vs 9%, P < .001) compared with patients with an aortobronchial fistula. 8 The surgical management principles of aortoenteric and aortobronchial fistulae are to obliterate the fistula tract, excise all infected tissue, and ensure an appropriate repair of both the arterial and other lumen. 9 In-hospital mortality has been reported at 3% after thoracic endovascular aortic repair (TEVAR) for aortobronchial fistula and 19% after TEVAR for aortoesophageal fistula (P ¼ .004) by Jonkers et al. 8 Acceptable results can be achieved when long-term, organismspecific antibiotic therapy is used. 8 However, many authors have voiced the opinion that endovascular repair should only be considered as a temporizing intervention for this problem and that definitive open repair should be considered when hemodynamic stability and control of associated infection been achieved. 10, 11 However, a binary logistic regression analysis showed prolonged antibiotic treatment was the only intervention associated with a significantly lower incidence of the aortic-related mortality.
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Aortobronchial fistula. Aortobronchial fistula is a rarely encountered clinical problem, and thoracic aortic aneurysmal disease is its most common etiology. Reports suggest that thoracic aortic disease is responsible for up to 50% of aortobronchial fistulae reported in the literature. Without intervention, this condition has reported mortality rates of 100%. [13] [14] [15] Thoracic aortic repair with a stent graft for aortobronchial fistulae appears to a viable alternative to conventional open repair with excellent short-term results. In fact, many consider that endovascular repair can be considered definitive treatment for patients presenting with a small aortobronchial fistula where there is no evidence of mediastinal infection on cross-sectional imaging at the time of the initial presentation and during follow-up. 16 The aortobronchial fistula can reoccur after endovascular repair and mandates long-term surveillance. Reviews have suggested a recurrence rate of 9.0%; the recurrence occurs at a mean of 13.2 months from the time of endovascular intervention. The cause of these late failures may be the occurrence of primary or secondary aortic infection and recurrent sepsis. Importantly, hemorrhagic-related complications are reported in one-third of patients with recurrence. 17 Up to 28% of the patients who receive a TEVAR for aortobronchial fistula will require reintervention due to late TEVAR failure. Reinfection has been attributed to stent graft contamination as a result of the fistula. Another issue raised is the potential for the stent graft to erode into adjacent organs, causing new fistula tracts and recurrent symptoms. In these patients, regardless of symptoms or clinical signs of sepsis, prolonged antibiotic therapy and life-long surveillance are considered good practice. However, there remains a need for Level I evidence to determine whether endovascular treatment of mycotic aneurysms of the thoracic and abdominal aorta is appropriate and sustainable. 14, 18 Endografts in extremity infection
In the presence of lower extremity infection, open surgical interventions have been reported to have a mortality rate of 2.8% in uncomplicated cases but rises to 20% in cases of infected pseudoaneurysms and even higher if emergency intervention is required. [19] [20] [21] Endovascular interventions with stent grafts have been intermittently documented in the treatment of lower extremity arterial mycotic aneurysm and ruptured infected anastomotic pseudoaneurysms. Klonaris et al 22 reported the successful management by emergency stent graft deployment to exclude the anastomotic femoral artery pseudoaneurysms in four patients, followed by subsequent surgical débride-ment and prescribing long-term antimicrobial therapy.
Intraoperative cultures grew S aureus in all patients. Similarly, several authors reported the use of endografts to treat bleeding femoral mycotic aneurysms in intravenous drug addicts. 23, 24 Krimato et al 25 reported a similar procedure for an infected pseudoaneurysm of the brachial artery. From the literature, it appears that endografting will allow hemorrhage control and that this should be followed by débridement and drainage coupled to long-term broad-spectrum antibiotics for mainly mixed bacterial infections. Follow-up is short, and 20% of patients suffered development of a new pseudoaneurysm or stent thrombosis, without reported limb loss.
Endografts in head and neck infections
Endografting for head and neck infections has been most commonly reported for carotid "blowout" syndrome and trachea-innominate fistulae. Both are considered erosive pathologies in the cervical circulation. Carotid blowout has a reported incidence of 3% to 4% in patients with primary squamous cell carcinoma of head and neck who have had a neck dissection, with or without tumor resection. 26 Carotid blowout events are most commonly associated with tumor, tumor surgery, or radiation therapy. Carotid blowout syndrome can be classified according to schema laid out by Chaloupka et al 27 as "threatened,"
where the carotid artery is exposed to the oral cavity or external environment via skin breakdown or by direct tumor invasion; "impending," in which sentinel bleeding has occurred but was controlled by conservative management; or "acute," where there is active bleeding. Tracheoinnominate artery fistulae are rare and almost always occur after tracheostomy, with a reported incidence of 0.1 to 1%. Open repair has been associated with mortality rates approaching 50%. 28, 29 Bleeding fistulae involving the external carotid or its branches are best managed by coil embolization.
Intervention of symptomatic fistulae with the internal carotid artery as the arterial source carries with it the risk of neurologic deficits. Parent vessel occlusion is still the preferred method of management, although placement of covered stents is an option in patients who are not candidates for parent vessel occlusion. The use of endovascular stents to control hemorrhage from carotid blowout and tracheoinnominate fistula compares favorably with other reported treatments for these disease processes. [30] [31] [32] In a 2007 survey of the literature, Sorial et al 33 identified
23 cases of emergency endografting for carotid blowout and three additional emergency endografts placed for tracheoinnominate fistulae. After endografting for carotid blowouts and tracheoinnominate fistula, only 9.5% of the carotid blowouts and none of the tracheoinnominate fistulae had systemic infectious complications. 33 In contrast, recurrent hemorrhage is reported in up to 31% of patients. The authors emphasized the importance of achieving generous landing zones in these cases compared with more bleeding events associated with penetrating trauma. Most authors recommend covering the entire artery that is involved with tumor to avoid a recurrence. It is important to realize that endovascular intervention is often the final intervention, because most patients with carotid blowout will die within months of the event secondary to the cancer. 33 Definitive consensus for the optimal treatment for carotid blowout syndrome and tracheoinnominate fistulae is lacking because there are no large randomized trials or prospective studies.
Endografts and the ureterovesical tract
Ureteroiliac artery fistula is an uncommon complication of pelvic surgery or radiation therapy. Common primary causes include aortoiliac aneurysm and arteriovenous malformation. 34 Secondary fistulae are often due to pelvic surgery with radiation therapy or vascular reconstruction. 35 The organisms that lead to infection of ureterovesical tract are generally Escherichia coli or other urinary pathogens. Estimated mortality from this condition is w9%, and the associated morbidity rate is 23%. Once diagnosed, placement of a covered stent, with or without embolization, is the most frequent endovascular intervention. Stent grafting for ureteroiliac artery fistula was first reported in 1996, 36 with >100 cases reported since that time. 37 Inadequate coverage can result from poor identification of the fistulous communication, or migration of the stent graft during placement is a common technical problem in these cases. 37 Procedural mortality is in the range of 7%, and follow-up in all patients is generally <1 year. No infections of the endografts have yet been reported.
Endografts in dialysis-access infections
Endografting in dialysis-access infections is very infrequent compared with open interventions. Klonaris et al 22 reported the successful management by emergency stent graft deployment to exclude anastomotic femoral artery pseudoaneurysms in two patients with femoral arteriovenous grafts. Once the patient is stabilized, surgical débridement is performed, and the patient is prescribed long-term antimicrobial therapy.
Endografts in visceral arterial infections
Mycotic visceral artery aneurysms are rare. There have been isolated reports on the use of endografts in the treatment of visceral artery mycotic aneurysms and infected pseudoaneurysms that involved the celiac, superior mesenteric, or inferior mesenteric arteries. 38, 39 In addition, several authors have reported the successful treatment of a mycotic aneurysms of the main renal artery. [40] [41] [42] Mycotic renal artery aneurysms are considered a complication of bacterial endocarditis. Most are found in distal intrakidney segments and as a result are usually more amenable to embolization rather than stent grafting. 41, 43 Case reports have also demonstrated the successful use of stent grafts for pseudoaneurysms and fistulae after various renal reconstructions.
CONCLUSIONS
Stent grafts remain an important and viable option for the treatment of mycotic aneurysms and infected pseudoaneurysms in anatomically or technically inaccessible locations. They also have a role in the immediate therapy for aortoesophageal and aortobronchial fistulae. In patients with a short life span (<6 months), no further intervention is generally required. In patients with a predicted life span >6 months, careful consideration should be given to a more definitive procedure. Life-long appropriate antibiotic therapy is strongly recommended for any patient receiving an endograft in an infected field. 
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